MODERN DRUGS AFFECTING LIPID METABOLISM IN ISCHEMIC HEART DISEASE
Vol. 2 No. 11 (2022): Eurasian Journal of Medical and Natural Sciences 111-116
Abstract
Stable ischaemic heart disease is a frequent and very heterogeneous condition. Drug therapy is important, in these patients, for improving their prognosis and controlling their symptoms. The typical clinical manifestation of obstructive coronary disease is angina pectoris. This symptom can be improved by various classes of compounds, namely beta-blockers (BBs), calcium antagonist, and nitrates. More recently, ranolazine and ivabradine have been introduced. All these drugs have been proven to reduce significantly angina. On the other hand, there are no evidences supporting improvement in prognosis, besides for the use of BBs, in patients with previous myocardial infarction (MI) or systolic dysfunction. Besides drugs for symptoms control, these patients also receive antiplatelet drugs, specifically aspirin, and lipid lowering compounds such as statins.
Keywords:
References
He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34. doi: 10.1056/NEJMsa050467.
Articles from European Heart Journal Supplements : Journal of the European Society of Cardiology are provided here courtesy of Oxford University Press
Baum SJ, Kris-Etherton PM, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, et al. Fatty acids in cardiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012;6(3):216–34. doi: 10.1016/j.jacl.2012.04.077.
Article from Barcelona Journal , Treatment of Ischaemic Heart Disease, 2015
Frayn KN, Fielding BA, Karpe F. Adipose tissue fatty acid metabolism and cardiovascular disease. Curr Opin Lipidol. 2005;16(4):409–15. doi: 10.1097/01.mol.0000171919.62129.6b.
Huddy K, Dhesi P, Thompson PD. Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins? Curr Atheroscler Rep. 2013;15(2):301. doi: 10.1007/s11883-012-0301-9.
Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815–31. doi: 10.1007/s40262-013-0075-4.
Gao ZY, Xu H, Shi DZ, Wen C, Liu BY. Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. J Ethnopharmacol. 2012;141(2):578–83. doi: 10.1016/j.jep.2011.08.071.
Readership
Downloads
Published
Issue
Section
How to Cite
